南新制藥(688189.SH)半年度淨利潤升40.97%至4951.63萬元
格隆匯 8 月 17日丨南新制藥(688189.SH)發佈2020年半年度報告,實現營業收入5.81億元,同比增長27.77%;歸屬於上市公司股東的淨利潤4951.63萬元,同比增長40.97%;歸屬於上市公司股東扣除非經常性損益的淨利潤4957.26萬元,同比增長45.81%;基本每股收益0.4042元。
為進一步優化在抗流感領域的產品結構,增強競爭實力,報告期內,公司積極推進流感領域的產品研發工作,各項目進展順利。目前,帕拉米韋吸入溶液在進行I/II期臨牀研究、帕拉米韋乾粉吸入劑在進行臨牀前研究、NX-2016正在進行成藥性研究、磷酸奧司他韋幹混懸劑已完成預BE。
帕拉米韋吸入溶液、帕拉米韋乾粉吸入劑、磷酸奧司他韋幹混懸劑和NX-2016這一系列抗流感藥物的研發和生產,讓公司對流感的發病機理、藥物臨牀前評價、臨牀方案制定和實施等有了深厚的積累,為公司更多抗流感新藥的研發上市奠定了基礎,從而構築了抗流感藥物領域的核心競爭優勢。
在抗腫瘤、抗病毒、糖尿病腎病等重大疾病治療領域,公司研發的主要產品美他非尼正在進行Ib/IIa期臨牀研究、鹽酸美氟尼酮正在進行I期臨牀研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.